Reflections and insights into the evolution of restrictive eligibility criteria for cancer clinical trials in China and beyond
Saved in:
| Main Authors: | Huiyao Huang, Huilei Miao, Jinling Tang, Ning Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Cancer Communications |
| Online Access: | https://doi.org/10.1002/cac2.70007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Leveraging Large Language Models for Clinical Trial Eligibility Criteria Classification
by: Sujan Ray, et al.
Published: (2025-04-01) -
Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion
by: Benjamin D. Mercier, et al.
Published: (2025-04-01) -
Challenging go/no-go decision scenarios and design recommendations in phase II oncology trials
by: Dandan Kong, et al.
Published: (2025-08-01) -
Examining equity-related eligibility criteria in clinical trials supporting 2022 US drug approvals.
by: Kathy Sliwinski, et al.
Published: (2025-01-01) -
Analysis of the adjustment of current eligibility criteria for alanine aminotransferase levels in blood screening in China
by: CHANG Le, et al.
Published: (2025-04-01)